Form Health’s Post

We are fortunately moving towards greater recognition that treating obesity is an important way to prevent and treat cardiometabolic co-morbidities. New studies are looking at how anti-obesity medications affect biopsy-proven Metabolic dysfunction–Associated SteatoHepatitis, or MASH. Tirzepatide (a dual agonist of GIP and GLP-1 receptors) treatment in MASH with moderate to severe fibrosis significantly increased resolution of MASH, without worsening fibrosis (by 62% at the highest dose). Survodutide (a novel dual agonist of glucagon and GLP-1 receptors) treatment in MASH and fibrosis (https://lnkd.in/ee6MQdDJ) in a phase 2 trial showed a reduction in MASH with no worsening of fibrosis, a decrease in liver fat by 30% and in fibrosis by at least one stage. MASH is part of the many cardiometabolic complications of obesity that reduce life expectancy. Losing weight is a key intervention. It is great to see studies conducted to help us establish that while obesity treatments lead to weight loss - perhaps even more importantly - they help prevent progression of metabolic disease.

https://lnkd.in/eXcn2hzV This is huge. Coming off my Muscular Dystrophy Association clinic today. #Obesity plagues our muscle Dystrophy patients. With obesity comes organ dysfunction. NASH is one example, and there is a new treatment. "#NASH is the more advanced form of nonalcoholic fatty #liver disease (NAFLD). Approximately 25% of US adults are estimated to have NAFLD,6 and of those patients, 20% may have NASH.7 Currently, the only treatment option available for these patients are #lifestyle and behavioral changes aimed at fat reduction, McIntyre explained. The new anti-obesity medications are being studied in NAFLD to focus on weight reduction,8 which could prevent NAFLD from developing into NASH with #fibrosis. The results of the phase 3, randomized controlled trial MAESTRO-NASH were recently published in New England Journal of Medicine.9 Overall, 25.9% of patients on 80-mg #resmetirom and 29.9% of patients on 100-mg resmetirom experienced NASH resolution with no worsening of fibrosis compared with just 9.7% on the placebo."

Norberto Chavez-Tapia 📢 Our latest research has just hit the shelves! 🎉 🔬 Our team delved into the intricate relationship between psoriatic diseases and liver fibrosis, uncovering some fascinating insights along the way. 🌟 Titled "Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross-sectional study," our study sheds light on the prevalence of liver fibrosis in psoriasis and identifies key predictors for its occurrence. 💡 Here's a sneak peek at what we found: Using non-invasive methods, we discovered significant fibrosis in 25% of patients, with 7.5% experiencing advanced fibrosis. Digging deeper, we unearthed a correlation between fibrosis and factors such as obesity, type 2 diabetes, and gamma-glutamyl transpeptidase levels. Surprisingly, our analysis revealed that the use of methotrexate wasn't associated with increased fibrosis risk, highlighting the role of metabolic dysfunction over medication in this context. 📊 Our findings underscore the importance of assessing metabolic factors in psoriatic patients and advocating for lifestyle modifications to mitigate the risk of liver fibrosis. 🌱 Together, let's spread awareness and empower healthier lives! Check out the full article for a deep dive into our groundbreaking research. Full (free) text 👇 https://lnkd.in/eJiUVbAA #Psoriasis #LiverHealth #MedicalResearch 🚀

Data for use of GLP1’s/GIP-GLP1 is getting stronger and stronger. I wonder when insurance companies will get on board.

Despite intensive preventive cardiovascular disease (CVD) efforts, substantial residual CVD risk remains even for individuals receiving all guideline-recommended interventions. Niacin is an essential micronutrient fortified in food staples, but its role in CVD is not well understood. In this study, untargeted metabolomics analysis of fasting plasma from stable cardiac patients in a prospective discovery cohort suggested that niacin metabolism was associated with incident major adverse cardiovascular events (MACE). Collectively, these results indicate that the terminal breakdown products of excess niacin, 2PY and 4PY, are both associated with residual CVD risk. They also suggest an inflammation-dependent mechanism underlying the clinical association between 4PY and MACE.

🗞️ This week's Metabolic News Weekly emphasizes the overlap of type 2 diabetes (#T2D) and metabolic dysfunction-associated steatotic liver disease (#MASLD), highlighting their shared risk factors and the efficacy of certain treatments. Key Insights: ⏵ #Obesity and insulin resistance are common risk factors for type 2 diabetes and MASLD. ⏵ #Retatrutide, a triple hormone receptor agonist, significantly reduces liver fat. ⏵ #Tirzepatide improves MASH resolution and fibrosis, promoting weight loss. ⏵ The dual #GLP-1 and glucagon receptor agonist, #survodutide, shows promising results in treating fatty liver disease. ⏵ The collaborative efforts of Boehringer Ingelheim and Zealand Pharma are enhancing GLP-1/glucagon receptor dual agonist therapies. Impact: ⏵ New therapies could significantly improve quality of life and treatment outcomes for patients with MASLD. ⏵ Enhancing understanding of metabolic diseases through shared risk factor management. ⏵ Potential shifts in therapeutic strategies for treating metabolic dysfunction. ⏵ Reduced healthcare costs through effective management of diabetes and liver disease. ⏵ Increased emphasis on personalized medicine in managing metabolic health. Check out the full edition here for this weeks news and more👇

#drug #diabetes #heartfailure #kidneydisease #clinicaltrials https://lnkd.in/e4J-2MPs Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinical trials of these therapies have demonstrated striking beneficial effects for various care goals, transforming the chronic disease therapeutic landscape. Cardiovascular safety studies in people with T2DM demonstrated that SGLT2 inhibitors reduce #cardiovascular death and hospitalization for heart failure. Subsequent trials in participants with heart failure with reduced or preserved left ventricular ejection fraction demonstrated that SGLT2 inhibitors have beneficial effects on heart failure outcomes. In dedicated kidney outcome studies, SGLT2 inhibitors reduced the incidence of #kidney failure among participants with or without diabetes. Post hoc analyses have suggested a range of other #benefits of these drugs in conditions as diverse as #metabolic dysfunction-associated steatotic liver disease, kidney stone prevention and anaemia. SGLT2 inhibitors have a generally favourable adverse effect profile, although patient selection and medication counselling remain important. Concerted efforts are needed to better integrate these agents into routine care and support long-term medication adherence to close the gap between clinical trial outcomes and those achieved in the real world.

This is an unsurprising result.

In a study, higher preoperative Leukocyte glucose index (LGI) leads to failure of long-term primary patency of arteriovenous fistula (AVF) after the initiation of dialysis in ESKD. AVF failure, leads to severe restenosis or AVF thrombosis and further dialysis would become impossible in those patients. The association was independent of age and sex, cardiovascular risk factors. It is elicited in a small number of patients, and it is unclear whether it is related to diabetes. LGI as a novel inflammatory biomarker based on blood leukocytes and glucose values and a predictor of COVID-19 severity before. #LeukocyteGlucoseIndex #AVFOcclusion #ESRD

🧪Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial💊 🔬 Study Highlights: 🔵 Conducted over 6 months, this phase 2 trial explored aspirin's effect on reducing liver fat content in adults with MASLD. 📅 🔵 Participants were given either 81 mg of aspirin daily or a placebo, revealing significant reductions in hepatic fat content for the aspirin group. 📉 🔵 Notably, aspirin led to a mean absolute change in hepatic fat content of -6.6% versus 3.6% with placebo, marking a critical step forward in MASLD treatment. 🎯 Key Outcomes: 🔵 Aspirin not only reduced hepatic fat levels but also increased the proportion of patients experiencing substantial reductions in liver fat. 🚀 🔵 Importantly, adverse events were comparable between the aspirin and placebo groups, highlighting the treatment's safety profile. 🛡️ 🤔 Looking Ahead: While these initial results are promising, further research in a larger cohort is essential to fully understand aspirin's role in MASLD management. 🌐 Could low-dose aspirin be the key to unlocking new pathways in liver health? link: https://lnkd.in/gWDdYumH #LiverHealth #ClinicalResearch #Aspirin #MASLD #InnovationInHealthcare